The FDA awarded Gene Solutions Breakthrough Device Designation to SPOT-MAS 10, a blood-based, adjunctive multiomics early detection test for ten cancer types in asymptomatic adults aged 40 and older. The assay uses machine learning to analyze cfDNA methylation and fragmentomic signatures. SPOT-MAS 10 is designed to cover five common cancers plus five aggressive but less common malignancies, including ovarian and pancreatic. Gene Solutions said it has a U.S. validation collaboration with Pangea Laboratories for analytical and clinical study work. The designation is intended to accelerate development for the test and highlights growing FDA attention on multiomics liquid biopsy platforms for early-stage detection settings.